The aim of the conference is to present the EESC’s proposal for the new strategy at a crucial moment in the EU landscape. With a new European Commission, a new European Parliament and a new budget programming period, it is now the perfect timing for a new Disability Strategy that fully takes into account the UN Convention on the Rights of Persons with Disabilities (UNCPRD), the Sustainable Development Goals and the 2030 Agenda for Sustainable Development.
Tackling socially determined inequalities in health, both between and within European Union (EU) Member States, is still a major challenge. This analysis describes the main concepts and gives examples for health inequalities across the EU. It then presents an overview of the work accomplished at international and EU levels. It shows, in particular, how the EU institutions, bodies and agencies have contributed to reducing health inequalities, notwithstanding that Member States have the main responsibility for health policy. The analysis then goes on to depict stakeholder views, before closing with an outlook on avenues for further action.
Partners in the PIONEER project have uploaded datasets from major studies, and are calling on others to do the same.
By European Society of Cardiology
Almost 1.2 million persons died from cancer in the European Union in 2016. Cancer was responsible for over one quarter (26%) of all deaths recorded in the EU.
By Lung Cancer Europe
Lung cancer is responsible for nearly 1 in 5 cancer related deaths in Europe, yet it remains a cancer that is underfunded and underrepresented. Previous research has demonstrated that many people impacted by lung cancer face disparities in access to diagnostics, treatment and care.
To mark World Cancer Day, LuCE has released its latest position paper which identifies disparities and challenges in access to lung cancer diagnostics and treatment across Europe. Data were collected through 34 healthcare professionals/researchers, 16 pharmaceutical companies and LuCE members (patient organizations).
The sessions at conference include the following: Biomarkers and molecular diagnosis, Prostate cancer – prevention and early diagnosis, Orphan regulation and personalised medicine, Realising the Potential of Data: The Million European Genome Declaration and the EU Digital Health Strategy, Health literacy and personalised healthcare.
This year, the EMCDDA celebrates 25 years of monitoring the drug situation in Europe. In the quarter of a century since the agency embarked on its first work programme in 1995, we have seen revolutionary changes, both in the extent and nature of the drugs problem, and in the world in which we live. Keeping pace with an increasingly dynamic drug phenomenon, while remaining relevant to policy and practice, requires constant reflection, innovation and agility. This is why we will be developing a new business model as we pursue our vision to contribute to a healthier and more secure Europe.
German health authorities confirmed a case of 2019-nCoV in Bavaria on 27 January. This brings the cases reported in Europe to four. The cases in France had a direct link to Wuhan, China.
By the Pharmaceutical Group of European Union
Each year PGEU conducts a survey among its membership to map the impact of medicine shortages across Europe from the community pharmacists’ perspective. The 2019 PGEU Medicine Shortages Survey Results cover the responses from 24 European countries.